BIOTE CORP -A (BTMD) Stock Overview
USA - NASDAQ:BTMD - US0906831039 - Common Stock
BTMD Key Statistics, Chart & Performance
The current stock price of BTMD is 2.98 USD. In the past month the price decreased by -13.87%. In the past year, price decreased by -41.91%.
BTMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 52 | 794.90B | ||
| JNJ | JOHNSON & JOHNSON | 18.86 | 454.31B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 15.17 | 264.96B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 19.21 | 264.50B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.96 | 256.29B | ||
| MRK | MERCK & CO. INC. | 11.58 | 222.78B | ||
| PFE | PFIZER INC | 8.07 | 155.61B | ||
| SNY | SANOFI-ADR | 11.41 | 124.14B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.75 | 92.51B | ||
| GSK | GSK PLC-SPON ADR | 9.59 | 87.33B | ||
| ZTS | ZOETIS INC | 23.54 | 64.89B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.34 | 46.11B |
Related stock screener links
About BTMD
Company Profile
biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas and currently employs 217 full-time employees. The company went IPO on 2021-03-02. The firm provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The company also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
Company Info
BIOTE CORP -A
1875 W. Walnut Hill Ln #100, Floor 5
Irving TEXAS US
Employees: 217
Phone: 19724869346
BIOTE CORP -A / BTMD FAQ
What is the stock price of BIOTE CORP -A today?
The current stock price of BTMD is 2.98 USD. The price decreased by -0.67% in the last trading session.
What is the ticker symbol for BIOTE CORP -A stock?
The exchange symbol of BIOTE CORP -A is BTMD and it is listed on the Nasdaq exchange.
On which exchange is BTMD stock listed?
BTMD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOTE CORP -A stock?
12 analysts have analysed BTMD and the average price target is 5.51 USD. This implies a price increase of 84.95% is expected in the next year compared to the current price of 2.98. Check the BIOTE CORP -A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOTE CORP -A worth?
BIOTE CORP -A (BTMD) has a market capitalization of 147.33M USD. This makes BTMD a Micro Cap stock.
How many employees does BIOTE CORP -A have?
BIOTE CORP -A (BTMD) currently has 217 employees.
What are the support and resistance levels for BIOTE CORP -A (BTMD) stock?
BIOTE CORP -A (BTMD) has a resistance level at 2.99. Check the full technical report for a detailed analysis of BTMD support and resistance levels.
Is BIOTE CORP -A (BTMD) expected to grow?
The Revenue of BIOTE CORP -A (BTMD) is expected to decline by -2.93% in the next year. Check the estimates tab for more information on the BTMD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOTE CORP -A (BTMD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BTMD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BTMD, evaluating the profitability, health, valuation and growth aspects
- BIOTE CORP -A (BTMD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOTE CORP -A (BTMD) Sales and EPS estimates to see what analysts future expectations are.
- BIOTE CORP -A (BTMD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOTE CORP -A (BTMD) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOTE CORP -A (BTMD) Stock Chart to make your own analysis
- BIOTE CORP -A (BTMD) Latest news and press-releases to stay up to date.
Does BIOTE CORP -A (BTMD) stock pay dividends?
BTMD does not pay a dividend.
When does BIOTE CORP -A (BTMD) report earnings?
BIOTE CORP -A (BTMD) will report earnings on 2025-11-10, after the market close.
What is the Price/Earnings (PE) ratio of BIOTE CORP -A (BTMD)?
The PE ratio for BIOTE CORP -A (BTMD) is 3.04. This is based on the reported non-GAAP earnings per share of 0.98 and the current share price of 2.98 USD. Check the full fundamental report for a full analysis of the valuation metrics for BTMD.
What is the Short Interest ratio of BIOTE CORP -A (BTMD) stock?
The outstanding short interest for BIOTE CORP -A (BTMD) is 2.91% of its float. Check the ownership tab for more information on the BTMD short interest.
BTMD Technical Analysis
BTMD Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BTMD. BTMD has an average financial health and profitability rating.
BTMD Financial Highlights
Over the last trailing twelve months BTMD reported a non-GAAP Earnings per Share(EPS) of 0.98. The EPS increased by 366.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.73% | ||
| ROA | 29.87% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BTMD Forecast & Estimates
12 analysts have analysed BTMD and the average price target is 5.51 USD. This implies a price increase of 84.95% is expected in the next year compared to the current price of 2.98.
For the next year, analysts expect an EPS growth of 166.59% and a revenue growth -2.93% for BTMD